

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):


- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

Figure 1

# MODULAR STRATEGY FOR DEVELOPING NON-PEPTIDE PROTEIN KINASE INHIBITORS



## KEY

- M<sub>1</sub> = Module consisting of a selection of validated functionalities for binding to the conserved catalytic residues.
- M<sub>2</sub> = Module consisting of a selection of non-peptide scaffolds for PTK's.
- S<sub>n</sub> = Specificity elements.

جیتو




Figure 3

General Module M<sub>1</sub> Design Features For Binding To The Conserved Protein Kinase Catalytic Region








Figure 4  
SUBSTRATE BEHAVIOR FOR BORONIC ACID PKA INHIBITORS 21 & 22



**Figure 5**  
**Binding interactions of src substrate**  
**Ac-Ile-Tyr-Gly-Glu-Phe-NH<sub>2</sub> in model src active site.**



[illegible]

1. The first step is to identify the problem. This involves understanding the current situation and the goals that need to be achieved.








Figure 8



**C**




Figure 10




Figure 11





Figure 12



**Figure 13**

(Residues are from the IRTK ternary structure and dotted bonds are H-bonds)





FIGURE 14



0040555-01300

FIGURE 15A

Ovarian Tumor N015 Sensitivity To Drugs:  
Suspended Cell Culture




FIGURE 15B

Normal Human Fibroblasts Sensitivity To  
Src Inhibitors: Subconfluent Cell Culture




FIGURE 15C

